V3V: FamiCord AG - Summary | Jitta

FamiCord AG

DEU:V3V

Price
€4.01
Loss Chance
54.1%
2.57JITTA SCORE
199.96%Over Jitta Line
Jitta Ranking
419 / 548
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (55)
Recent Business Performance (31)
Financial Strength (46)
Return to Shareholders (0)
Competitive Advantage (41)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Cash Conversion CycleLess than 60 days
Revenue and EarningEarning loss detected in 2025
Operating MarginInconsistent
CapExVery High
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
2.57
199.96%
4.17
65.16%
Health Care Services
5.50
46.75%
4.68
102.35%
COMPANY DESCRIPTION
FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the company provides biobanking services, such as freezing sperm and storage of adipose tissue and the isolation of cells from the stored materials. The company was formerly known as VITA 34 AG and changed its name to FamiCord AG in February 2025. FamiCord AG was founded in 1997 and is based in Leipzig, Germany.